Auxilium Pharma/Endo Pharma terminates agreement to market Stendra (avanafil) for erectile dysfunction in the US and Canada- Vivus
Auxilium Pharmaceuticals, a subsidiary of Endo Pharma, has announced in a regulatory filing that it will terminate its licensing agreement with Vivus Inc. for marketing Stendra (avanafil) in the USA and Canada. Auxilium has given the 6 months' notice that is required to cancel the agreement, which means termination by 30 June 2016.
Endo may be seeking to focus resources on its new product Belbuca, a long-term opioid film that was approved by the FDA in October 2015 to treat patients with severe chronic pain. Additionally in its Q3 earnings filing, Endo noted that it had "experienced underperformance with respect to Stendra" due to a "sustained downturn" in the market for short-acting testosterone replacement therapies.
Comment: Avanafil is marketed as Spedra in Europe, Australia and New Zealand by Menarini group.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins